What's Going In With Vivek Ramaswamy-Founded Roivant Sciences Stock On Monday? - Immunovant ( NASDAQ:IMVT ) , Roivant Sciences ( NASDAQ:ROIV )
Monday, Immunovant, Inc. IMVT reported results from the Phase 2a trial of batoclimab in Graves' Disease, an immune system condition that affects the thyroid gland. It causes the body to make too much thyroid hormone. Immunovant is a member of the Roivant Sciences Ltd. ROIV family of companies.
| Ticker |
Sentiment |
Impact |
|
IMVT
|
Somewhat Bullish
|
70 %
|
|
ROIV
|
Neutral
|
30 %
|
